This study looks at how effective and safe a medicine called setidegrasib is when given with two types of chemotherapy for pancreatic cancer. The focus is on adults with a specific faulty gene, known as the KRAS G12D mutation, who have cancer that has spread. The main goal is to see if setidegrasib helps people live longer than those who only receive a placebo with chemotherapy. Researchers also want to understand how well the body processes this medicine and its safety when used together with chemotherapy.
The trial's ID number is NCT07409272. It is a Phase 3 study, meaning it is looking at how well the treatment works and how safe it is. This trial is regulated by the FDA and aims to include about 614 participants.
Who can join
Adults aged 18 and older can join the study if they have been diagnosed with metastatic pancreatic cancer that shows the KRAS G12D mutation. They must not be able to have surgery or radiation to cure their cancer. The study is not open to those with certain other health issues or other active cancers that need treatment. The trial team will confirm if a person is eligible to participate.
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of two groups. One group will receive setidegrasib along with chemotherapy (either mFOLFIRINOX or NALIRIFOX), while the other group will get a placebo with the same chemotherapy. Everyone will receive treatment for a cycle of 28 days, and the treatments will be given through an intravenous infusion.
Where
This trial is enrolling at 28 locations. Recruiting sites are listed first.
AGH Singer Research Institute
Pittsburgh, Pennsylvania
Recruiting
Allina Health Cancer Institute - Hematology Cancer Care Services
Minneapolis, Minnesota
Recruiting
Atlantic Health - Overlook Medical Center
Morristown, New Jersey
Recruiting
Baptist MD Anderson Cancer Institute
Jacksonville, Florida
Recruiting
Brown University Health Cancer Institute - Division of Hematology/Oncology
Providence, Rhode Island
Recruiting
Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led global trials in liver and bile duct cancer. Treats pancreatic cancer, gallbladder cancer, bile duct cancer and liver cancer. Offers targeted therapy.
Directs genitourinary oncology at Huntsman Cancer Institute. Treats pancreatic cancer, liver cancer, gallbladder cancer and esophageal cancer. Also treats stomach cancer and colorectal cancer.